Cargando…

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

CONTEXT: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin. OBJECTIVE: To demonstrate the superiority of semag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodbard, Helena W, Lingvay, Ildiko, Reed, John, de la Rosa, Raymond, Rose, Ludger, Sugimoto, Danny, Araki, Eiichi, Chu, Pei-Ling, Wijayasinghe, Nelun, Norwood, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2018
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991220/ https://www.ncbi.nlm.nih.gov/pubmed/29688502 http://dx.doi.org/10.1210/jc.2018-00070

Ejemplares similares

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1‐5 trials
por: Warren, Mark, et al.
Publicado: (2018)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
por: Husain, Mansoor, et al.
Publicado: (2020)

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)
por: Rodbard, Helena W., et al.
Publicado: (2017)

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
por: McCrimmon, Rory J., et al.
Publicado: (2020)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis
por: Araki, Eiichi, et al.
Publicado: (2022)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
por: Leiter, Lawrence A., et al.
Publicado: (2019)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Case report: A comatose patient with pregabalin overdose successfully treated with continuous renal replacement therapy
por: Nielsen, Visti Torbjørn, et al.
Publicado: (2023)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial
por: Ahmann, A., et al.
Publicado: (2015)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
por: Wilding, John P. H., et al.
Publicado: (2022)

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
por: Guzauskas, Gregory F, et al.
Publicado: (2021)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy
por: Langer, Jakob, et al.
Publicado: (2019)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q0ajm9876f36monjjmapf6soht